StockData
Century Therapeutics, Inc. logo

Century Therapeutics, Inc. (IPSC) stock

IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.65+0.02 (+1.23%)

Close on Nov 13, 2026Market cap $298.77MP/E –Yield –

Earnings

Century Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.11
-$0.40 a year earlier
Latest guidance
Issued
Nov 5, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Century Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open––-$0.11Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026before the open––-$0.17Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open––-$0.11Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open––-$0.40Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025after the close––-$0.38Release
Q1 FY2025ended Mar 31, 2025May 15, 2025after the close$109.20M+12033.3%$0.89Release
Q4 FY2024ended Dec 31, 2024Mar 19, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024before the open$800.00K+700.0%-$0.37Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$800.00K+700.0%-$0.38Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$900.00K-47.1%-$0.45Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Century Therapeutics guided for has been reported

Guidance history

Every forecast Century Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2024generally accepted accounting principles (GAAP) operating expensesfull year$150.00M – $160.00M–
Aug 8, 2024operating expensesFY2024$150.00M – $160.00MReaffirmed
May 9, 2024generally accepted accounting principles (GAAP) operating expensesFY2024$150.00M – $160.00MRaised
Mar 14, 2024generally accepted accounting principles (GAAP) operating expensesFY2024$135.00M – $145.00MNew
Nov 9, 2023GAAP Operating ExpensesFY2023$135.00M – $145.00MRaised
Nov 9, 2023non-cash stock-based compensation expenseFY2023$12.00M – $17.00MNew
Aug 9, 2023operating expensesFY2023$135.00M – $145.00MReaffirmed
Aug 9, 2023non-cash stock-based compensation expenseFY2023$12.00M – $17.00MLowered
May 11, 2023non-cash stock-based compensation expenseFY2023$12.00M – $17.00MReaffirmed
May 11, 2023operating expensesFY2023$135.00M – $145.00MReaffirmed
Mar 16, 2023non-cash stock-based compensation expenseFY2023$12.00M – $17.00MNew
Mar 16, 2023operating expensesFY2023$135.00M – $145.00MNew
Nov 10, 2022GAAP operating expensesFY2022$140.00M – $145.00MLowered
Aug 11, 2022non-cash stock-based compensation expenseFY2022$10.00M – $15.00MReaffirmed
Aug 11, 2022GAAP Operating ExpensesFY2022$155.00M – $165.00MReaffirmed
May 16, 2022non-cash stock-based compensation expenseFY2022$10.00M – $15.00MReaffirmed
May 16, 2022GAAP Operating ExpensesFY2022$155.00M – $165.00MReaffirmed
Mar 17, 2022non-cash stock-based compensation expenseFY2022$10.00M – $15.00MNew
Mar 17, 2022GAAP Operating ExpensesFY2022$155.00M – $165.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Century Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Century Therapeutics Reports Third Quarter 2026 Financial Results
    Results
  2. CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
    Update
  3. CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research
    Update
  4. Joseph Truitt to Board of Directors
    Update
  5. Century Therapeutics Reports Second Quarter 2026 Financial
    Results
  6. Quarterly results release
    Results
  7. New CNTY-813 Preclinical Data Demonstrate Durable
    News
  8. Scalable Production of Allo-Evasion 5.0-
    News
  9. Century Therapeutics Reports First Quarter Financial Results
    Results
  10. Century Therapeutics Reports Full Year 2025
    Results
  11. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to,
    Results
  12. Unlocking the Value of our Pipeline for T1D January 2026
    Update
  13. Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for
    Update
  14. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to,
    Update
  15. Corporate Deck – December 2025
    Update

See a number that looks wrong?